| 1 | bone health for every | | | | | | | 2 | 0.29% |
| 2 | best bone health for | | | | | | | 2 | 0.29% |
| 3 | for children’s bone health | | | | | | | 2 | 0.29% |
| 4 | society for children’s bone | | | | | | | 2 | 0.29% |
| 5 | international society for children’s | | | | | | | 2 | 0.29% |
| 6 | health for every child | | | | | | | 2 | 0.29% |
| 7 | pharma is a rare | | | | | | | 1 | 0.14% |
| 8 | create and deliver novel | | | | | | | 1 | 0.14% |
| 9 | a japanbased global specialty | | | | | | | 1 | 0.14% |
| 10 | as a japanbased global | | | | | | | 1 | 0.14% |
| 11 | value as a japanbased | | | | | | | 1 | 0.14% |
| 12 | lifechanging value as a | | | | | | | 1 | 0.14% |
| 13 | biomarin is a world | | | | | | | 1 | 0.14% |
| 14 | deliver novel medicines with | | | | | | | 1 | 0.14% |
| 15 | and deliver novel medicines | | | | | | | 1 | 0.14% |
| 16 | kirin strives to create | | | | | | | 1 | 0.14% |
| 17 | to create and deliver | | | | | | | 1 | 0.14% |
| 18 | strives to create and | | | | | | | 1 | 0.14% |
| 19 | company with a heritage | | | | | | | 1 | 0.14% |
| 20 | kyowa kirin strives to | | | | | | | 1 | 0.14% |
| 21 | is a world leader | | | | | | | 1 | 0.14% |
| 22 | a world leader in | | | | | | | 1 | 0.14% |
| 23 | world leader in developing | | | | | | | 1 | 0.14% |
| 24 | leader in developing and | | | | | | | 1 | 0.14% |
| 25 | 3300 within rare disease | | | | | | | 1 | 0.14% |
| 26 | in developing and commercializing | | | | | | | 1 | 0.14% |
| 27 | countries out of which | | | | | | | 1 | 0.14% |
| 28 | 80 countries out of | | | | | | | 1 | 0.14% |
| 29 | japanbased global specialty pharmaceutical | | | | | | | 1 | 0.14% |
| 30 | with a heritage of | | | | | | | 1 | 0.14% |
| 31 | people in 80 countries | | | | | | | 1 | 0.14% |
| 32 | with significant morbidity mortality | | | | | | | 1 | 0.14% |
| 33 | nephrology oncology immunologyallergy and | | | | | | | 1 | 0.14% |
| 34 | including nephrology oncology immunologyallergy | | | | | | | 1 | 0.14% |
| 35 | areas including nephrology oncology | | | | | | | 1 | 0.14% |
| 36 | society across multiple therapeutic | | | | | | | 1 | 0.14% |
| 37 | and society across multiple | | | | | | | 1 | 0.14% |
| 38 | patients and society across | | | | | | | 1 | 0.14% |
| 39 | of patients and society | | | | | | | 1 | 0.14% |
| 40 | needs of patients and | | | | | | | 1 | 0.14% |